NCT00245063

AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

Phase II Study of AZD2171 in Patients With Recurrent Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: National Cancer Institute (NCI) · NIH
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase II trial is studying how well AZD2171 works in treating patients with recurrent small cell lung cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Detailed description

PRIMARY OBJECTIVES: I. To determine the objective response rate of AZD 2171 in patients with recurrent small cell lung cancer (SCLC). SECONDARY OBJECTIVES: I. To determine the overall survival and time to progression. II. To assess the toxicities associated with the administration of AZD 2171 for patients with recurrent SCLC. III. To perform molecular correlative studies on archival tumor and peripheral blood. OUTLINE: This is a multicenter study. Patients receive oral AZD2171 once daily for 28 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 4 weeks.

Conditions

• Recurrent Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	cediranib maleate	Given PO
OTHER	laboratory biomarker analysis	Correlative studies
OTHER	pharmacogenomic studies	Optional correlative studies

Timeline

• Start date: 2006-03-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2005-10-27
• Last updated: 2014-10-02
• Results posted: 2014-10-02

Locations

1 site across 1 country: United States